Strategies for Communication and Collaboration in Prostate Cancer CareDecember 15th 2022
Boris Gershman, MD discusses recent advancements in prostate cancer imaging, touching on the clinical application of multiparametric MRI (mpMRI), effective strategies for communication between urologists and radiologists, and how machine learning may shape the future of prostate cancer imaging.
Biomarker Testing for Risk Assessment of Patients Suspected of Having Prostate CancerDecember 14th 2022
Gerald Andriole, MD discusses pre-biopsy biomarker testing as a risk assessment tool in patients suspected of having prostate cancer, highlighting key advantages and reviewing available options and clinical data, and shares his clinical experience regarding implementation.
Focal Therapy Options for Localized Prostate CancerAugust 2nd 2022
Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci, provides a historical perspective on treatment options for clinically localized prostate cancer, reviews emerging focal therapy options including HIFU, and discusses how focal therapy has impacted the field.
Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate CancerJuly 20th 2022
Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.
Implantable Tibial Nerve Stimulation Devices for Treatment of Overactive BladderMarch 2nd 2022
This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.
18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical RecurrenceDecember 22nd 2021
Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.